My name is Lars Fruergaard Jorgensen, and I'm the CEO of Novo Nordisk. With me today, I have executive vice president and head of commercial strategy and corporate affairs, Camilla Sylvest; executive vice president and head of North America operations, Doug Langa; executive vice president and head of development, Martin Holst Lange; and finally, chief financial officer, Karsten Munk Knudsen.
Novo Nordisk (NVO) reports mixed results for Q4 as earnings beat estimates but sales miss on the same. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
SNY vs. NVO: Which Stock Is the Better Value Option?